Adage Capital Partners Gp, L.L.C. Nuvalent, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 680,000 shares of NUVL stock, worth $53 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
680,000
Previous 280,000
142.86%
Holding current value
$53 Million
Previous $28.6 Million
85.83%
% of portfolio
0.1%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
230Shares Held
58.9MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$418 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$351 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$236 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$204 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.35B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...